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Rationale: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial
pneumonia. The pathogenicity of IPF has been widely investigated but still remains to be clar-
ified. Efferocytosis, the specialized recognition and ingestion of apoptotic cells by phagocytes,
is essential for the resolution of inflammation in the lungs and repair of injured tissues.
Impaired efferocytosis contributes to the pathogenesis of chronic lung diseases such as emphy-
sema and cystic fibrosis. We hypothesized that efferocytosis would also be reduced in alveolar
macrophages isolated from subjects with IPF.
Methods: Efferocytosis, was evaluated using Wright-Giemsa stained cell preparations isolated
from the bronchoalveolar lavage (BAL) fluid of patients with IPF (n Z 5), nonspecific intersti-
tial pneumonitis (n Z 6), cryptogenic organizing pneumonia (n Z 4) and eosinophilic pneu-
monia (EP) (n Z 5).
Results: Uningested apoptotic cells were significantly higher in BAL fluid from patients with IPF
compared to other forms of interstitial lung disease. Macrophages isolated from patients with
eosinophilic pneumonia had significantly fewer phagocytic ingestions than macrophages from
the other three groups.
Conclusion: Efferocytosis by alveolar macrophages was significantly lower in subjects with IPF
compared to subjects with other interstitial pneumonia. Dysregulated efferocytosis may
contribute to the pathogenesis of IPF.
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Efferocytosis, the specialized recognition and ingestion of
apoptotic cells by phagocytes, has been shown to down-
regulate inflammation by decreasing inflammatory medi-
ator production via production of TGF-b1, PGE2 and IL-10.1
At the same time, efferocytosis drives tissue repair by
upregulating cellular production of growth factors such as
hepatocyte growth factor (HGF).2 Impaired efferocytosis
has been documented in a number of chronic respiratory
diseases (e.g. COPD, cystic fibrosis and asthma) and
contributes directly to their pathogenesis by enhancing
inflammation and impairing epithelial repair.3,4 Abnormal
accumulation of inflammatory cells and dysregulated
epithelial repair have been suggested to contribute to the
development of fibrotic lung diseases. Accordingly, we
sought to determine if efferocytosis was impaired in
patients with idiopathic pulmonary fibrosis (IPF) and less-
fibrotic idiopathic interstitial pneumonias (IIPs) such as
nonspecific interstitial pneumonia (NSIP) and cryptogenic
organizing pneumonia (COP).5
Methods
Efferocytosis, was evaluated using Dif-Quik stained cell
preparations isolated from the bronchoalveolar lavage
(BAL) fluid of patients with IPF (n Z 5), NSIP (n Z 6), COP
(n Z 4) and eosinophilic pneumonia (EP) (n Z 5). We
analyzed BAL from EP because it is rapidly reversible non-
fibrotic lung disease. All BAL were performed at the time
of diagnosis of IIP or EP. IPF was diagnosed according to
ATS/ERS criteria(5) or UIP pattern by surgical biopsy. NSIP
and COP were diagnosed by surgical biopsy or trans-
bronchial lung biopsy (TBLB). EP was diagnosed by clinical
findings including BAL and TBLB. We excluded cases in
which collagen vascular diseases, infection or pneumoco-
niosis were present. Patient characteristics are available as
online Supplementary data. Macrophages containing
apoptotic bodies and apoptotic cells with condensed
nuclei3 were identified as shown in Fig. 1a. Efferocytosis
was quantified using the following formulas:
Phagocytic indexðPIÞZ
number of phagocytosed cells=number of AMs 100
Apoptoticcellsð%ÞZ
numberofapoptoticcells=ðtotalcellsnumberofAMsÞ
100
Defective indexðDIÞZapoptotic cellsð%Þ=PI
Results
Phagocytic indexes were significantly lower in BAL obtained
from patients with IIPs compared to EP (Fig. 1b). In addi-
tion, higher percentages of apoptotic cells were present in
BAL from IPF patients (Fig. 1c) with corresponding elevation
of the defective index (Fig. 1d), suggesting that clearanceof apoptotic cells by AMs may be defective in IPF compared
to other forms of IIP that have better clinical outcomes.Discussion
Efferocytosis of dying cells is critical for the resolution of
inflammation and repair of injured tissues. Efficient
removal of apoptotic cells prevents the release of poten-
tially toxic intracellular contents from the dying cells and
enhances the production of growth factors and cytokines by
the phagocyte, including TGF-b and HGF. The anti inflam-
matory effects of efferocytosis (i.e. through TGF-b produc-
tion) may be considered of paramount importance in
resolving inflammation in lung diseases where leukocyte
infiltration plays a role, such as EP, COP and NSIP. On the
other hand, sustained production of TGF-b may lead to
fibrosis. In comparison, HGF enhances epithelial cell repair
and may counteract the pro-fibrotic effects of TGF-b. Thus
in non-inflammatory injury processes (such as IPF) the
production of HGF may be of greater importance in driving
epithelial repair. In other words, the normal resolution of
inflammation and the initiation of lung repair almost
certainly require a delicate balance between the produc-
tion of anti-inflammatory factors (TGF-b) and molecules
that stimulate repair (HGF). In this context, both the nature
of the underlying disease and the timing of apoptotic cell
clearance may be critical, such that impaired efferocytosis
during early lung injury may delay the resolution of
inflammation whereas during later phases, failure to clear
apoptotic cells may result in disordered repair.
Alveolar macrophages are the most abundant leukocytes
in the airspaces and are the major cell responsible for
efferocytosis. Their programming (or activation) is highly
dependent on the environment in which they reside.
Accordingly, macrophages that exist in a Th1 environment
are generally pro-inflammatory and “classically activated”.
Conversely, a Th2 environment promotes the development
of “alternatively activated” macrophages that produce
molecules implicated in mesenchymal repair and fibrosis. It
is therefore not surprising that AMs taken from patients with
IPF exhibit features of alternative activation.6 As such, it has
been suggested that they may contribute to fibrosis by
producing TGF-b and CCL18.6 Indeed, intentional depletion
of alveolar macrophages in animal models of IPF abrogates
the development of fibrosis.7 Similar results have been ach-
ieved by inhibiting alternative macrophage activation.8
Interestingly, debris from dead or dying cells that have not
been effectively clearedmay promote alternative activation
of macrophages.9 This raises the intriguing possibility that
the presence of apoptotic cells drives alternative activation
of macrophages, which in turn enhances fibroproliferation.
Nuclear condensation, cytoplasmic membrane blebbing,
and reduced cell volume are morphologic hallmarks of
apoptosis. Unfortunately, these changes make it difficult to
distinguish the source (or origin) of apoptotic bodies. There-
fore we cannot be sure whether the apoptotic cells identified
in our study are effete leukocytes or sloughed epithelial cells.
Since neutrophils and macrophages isolated from BAL of
patients with IPF are resistant to apoptosis10,11 we favor the
latter, especially since lung tissue from patients with IPF
contains high numbers of apoptotic epithelial cells.12
Figure 1 a) Representative findings of Dif-Quik stained cell preparations isolated from the bronchoalveolar lavage (BAL) fluid.
Top two panels show efferocytosis. Bottom panels demonstrate apoptotic cells. b e d) Phagocytic indexes (PI) (b), percentages
of apoptotic cells (c) and defective index (DI) (d) in BAL cells from patients with IIPs and EP. Statistical analysis was performed by
two-way ANOVA, followed by Student Newman Keuls test for multiple comparisons.
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accelerated cell death or defective apoptotic cell removal.
Since under most circumstances, clearance of apoptotic
cells from injured tissues is incredibly efficient, we suggest
that our results reflect the latter. For example, during
bacterial pneumonia there are over 106 neutrophils per
mm3 of lung tissue, yet clearance of dying neutrophils is so
efficient that less than 0.3% are apoptotic.13 On the other
hand, impaired clearance of apoptotic cells has been sug-
gested as a mechanism to explain the high levels of
apoptotic cells noted in the parenchyma and airspaces in
patients with COPD(4). While our study suggests that
efferocytosis may be impaired in IPF, prospective research
using primary cells taken from patients with IIPs is required
to clarify this finding and determine the mechanisms that
underlie this defect.Conflict of interest
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